EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study

Peng Zhao, Zhuo-Yu An, Hai-Xia Fu iD, Hui-Xin Liu, Cheng-Jie Feng, Qiu-Sha Huang, Jin Wu, Ye-Jun Wu, Li-Ping Yang, Qing-Yuan Qu, Yu-Xiu Chen, Meng-Lin Li und 13 weitere

American Journal of Hematology · 2024-10 · 99 (10) · 1951-1958

DOI: 10.1002/ajh.27433 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift American Journal of Hematology, online erschienen am 09.07.2024. Verfasst von Peng Zhao und 24 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Pyrazoles, Sulfonamides, Azetidines, Purines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Programme, Capital Health Research and Development of Special Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with steroid‐resistant or relapsed immune thrombocytopenia (ITP) suffer increased bleeding risk and impaired quality of life. Baricitinib, an oral Janus‐associated kinases (JAK) inhibitor, could alleviate both innate and adaptive immune disorders without inducing thrombocytopenia in several autoimmune diseases. Accordingly, an open‐label, single‐arm, phase 2 trial (NCT05446831) was initiated to explore the safety and efficacy of baricitinib in ITP. Eligible patients were adults with primary ITP who were refractory to corticosteroids and at least one subsequent treatment, and had platelet counts below 30 × 10 9 /L at enrolment. Participants received baricitinib 4 mg daily for 6 months. The primary endpoint was durable response at the 6‐month follow‐up. A total of 35 patients were enrolled. Durable response was achieved in 20 patients (57.1%, 95% confidence interval, 39.9 to 74.4), and initial response in 23 (65.7%) patients. For patients responding to baricitinib, the median time to response was 12 (IQR 6–20) days, and the median peak platelet count was 94 (IQR 72–128) × 10 9 /L. Among the 27 patients undergoing extend observation, 12 (44.4%) remained responsive for a median duration of approximately 20 weeks after baricitinib discontinuation. Adverse events were reported in 11 (31.4%) patients, including infections in 6 (17.1%) patients during the treatment period. Treatment discontinuation due to an adverse event was reported in 2 (5.7%) patients. Evidence from this pilot study suggested that baricitinib might be a novel candidate for the armamentarium of ITP‐modifying agents. Future studies are warranted to validate the safety, efficacy, and optimal dosing of baricitinib in patients with ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesSulfonamidesAzetidinesPurinesPurpura, Thrombocytopenic, IdiopathicDrug ResistanceHumansMalePilot ProjectsFemaleMiddle AgedAdultAgedRecurrenceTreatment OutcomePlatelet Count

Substanzen

PyrazolesbaricitinibSulfonamidesAzetidinesPurines

Autor:innen und Institutionen

  • Peking University Institute of Hematology, Peking University People's Hospital, Beijing, China.
  • National Clinical Research Center for Hematologic Disease, Beijing, China.
  • Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Collaborative Innovation Center of Hematology, Peking University, Beijing, China.
  • Department of Clinical Epidemiology, Peking University People's Hospital, Beijing, China.

ORCID-Profile: Hai-Xia Fu, Xiao-Lu Zhu, Xiao-Hui Zhang

Förderung

  • National Natural Science Foundation of China
  • Key Programme
  • Capital Health Research and Development of Special Fund
  • National Key Research and Development Program of China

Zitieren

APA

Zhao, P., An, Z. Y., Fu, H. X., Liu, H. X., Feng, C. J., Huang, Q. S., Wu, J., Wu, Y. J., Yang, L. P., Qu, Q. Y., Chen, Y. X., Li, M. L., Wang, C. C., Chen, Q., Zhu, X. L., He, Y., Zhang, Y. Y., Jiang, Q., Jiang, H., …, & Zhang, X. H. (2024). Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study. American Journal of Hematology, 99(10), 1951-1958. https://doi.org/10.1002/ajh.27433

Vancouver

Zhao P, An ZY, Fu HX, Liu HX, Feng CJ, Huang QS, et al. Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study. American Journal of Hematology. 2024;99(10):1951-1958. doi:10.1002/ajh.27433

BibTeX
@article{Zhao2024,
  author = {Zhao, Peng and An, Zhuo-Yu and Fu, Hai-Xia and Liu, Hui-Xin and Feng, Cheng-Jie and Huang, Qiu-Sha and Wu, Jin and Wu, Ye-Jun and Yang, Li-Ping and Qu, Qing-Yuan and Chen, Yu-Xiu and Li, Meng-Lin and Wang, Chen-Cong and Chen, Qi and Zhu, Xiao-Lu and He, Yun and Zhang, Yuan-Yuan and Jiang, Qian and Jiang, Hao and Lu, Jin and Chang, Ying-Jun and Zhao, Xiao-Su and Zhao, Xiang-Yu and Huang, Xiao-Jun and Zhang, Xiao-Hui},
  title = {Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot study},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {10},
  pages = {1951--1958},
  doi = {10.1002/ajh.27433}
}
Kostenlos starten →